X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.globenewswire.com/news-release/2024/06/24/2902888/0/en/TOFIDENCE-tocilizumab-a-Biosimilar-Referencing-ROACTEMRA-Approved-in-the-European-Union.html
https://www.ema.europa.eu/en/documents/overview/tofidence-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2024/04/25/2870053/0/en/Biogen-Receives-Positive-CHMP-Opinion-for-TOFIDENCE-tocilizumab-a-Biosimilar-Referencing-ROACTEMRA.html
https://www.prnewswire.com/news-releases/celltrion-usa-completes-submission-of-biologics-license-application-for-ct-p47-a-biosimilar-candidate-of-actemra-tocilizumab-302046308.html
https://www.reuters.com/business/healthcare-pharmaceuticals/roche-settles-us-patent-lawsuit-against-biogen-over-blockbuster-arthritis-drug-2023-10-23/
https://www.prnewswire.com/news-releases/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions-301950199.html
https://www.ema.europa.eu/en/documents/overview/tyenne-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2023/09/29/2752273/0/en/FDA-Approves-Biogen-s-TOFIDENCE-tocilizumab-bavi-a-Biosimilar-Referencing-ACTEMRA.html
https://www.fresenius-kabi.com/news/european-commission-approval-tyenne-tocilizumab-biosimilar
https://www.nasdaq.com/articles/roche-sues-biogen-over-biosimilar-of-blockbuster-arthritis-drug
https://www.pharmatimes.com/news/trio_of_covid-19_treatments_receive_nice_nod_1488312
https://www.pharmafile.com/news/743849/new-monoclonal-antibody-hospitalised-covid-19-patients-approved-fda
https://www.globenewswire.com/news-release/2022/12/21/2578198/0/en/FDA-approves-Roche-s-Actemra-for-the-treatment-of-COVID-19-in-hospitalised-adults.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-lab-completes-phase-1-study-of-proposed-arthritis-drug/articleshow/96339880.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-lab-completes-phase-1-study-of-proposed-arthritis-drug/articleshow/96339880.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.globenewswire.com/news-release/2022/12/09/2570970/0/en/FDA-Accepts-Biogen-Biologics-License-Application-for-BIIB800-A-Biosimilar-Candidate-Referencing-ACTEMRA-tocilizumab.html
https://www.pharmaceutical-technology.com/news/roche-actemra-iv-covid-19/
https://www.pharmaceutical-technology.com/news/roche-actemra-covid-19-treatment/
https://www.globenewswire.com/news-release/2022/09/30/2525870/0/en/Biogen-Announced-EMA-Filing-Acceptance-of-BIIB800-A-Biosimilar-Candidate-Referencing-RoACTEMRA-tocilizumab.html
https://koreajoongangdaily.joins.com/2022/07/19/business/industry/korea-celltrion-actemra/20220719141050983.html
https://www.globenewswire.com/news-release/2022/06/03/2455972/0/en/Biogen-and-Bio-Thera-Solutions-Present-Positive-Phase-3-Data-for-Tocilizumab-Biosimilar-Candidate-at-the-Annual-European-Congress-of-Rheumatology-EULAR-2022.html
http://www.koreabiomed.com/news/articleView.html?idxno=13704
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276
https://www.pharmaceutical-technology.com/news/roche-actemra-who-prequalification/
https://www.who.int/news/item/11-02-2022-who-prequalifies-first-monoclonal-antibody---tocilizumab-to-treat-covid-19
https://www.prnewswire.com/news-releases/calcimedica-initiates-cardea-plus-a-clinical-trial-of-auxora-in-patients-with-critical-covid-19-pneumonia-301464344.html
https://www.famhp.be/en/news/limited_availability_of_roactemra_roche_new_situation_update
https://www.famhp.be/en/news/limited_availability_of_roactemra_roche_new_situation_update
https://endpts.com/genentechs-tocilizumab-shortage-due-to-covid-19-now-hits-car-t-recipients-with-fda-offering-alternatives-to-help/
https://www.europeanpharmaceuticalreview.com/news/166196/ema-recommends-roactemra-in-adults-with-severe-covid-19/
https://www.contractpharma.com/contents/view_breaking-news/2021-12-07/ema-expands-authorization-for-roches-actemraroactemra-in-covid/?widget=listSection
https://www.globenewswire.com/news-release/2021/12/07/2347122/0/en/Actemra-RoActemra-approved-by-the-European-Commission-to-treat-patients-with-severe-COVID-19.html
https://www.tga.gov.au/media-release/tga-provisional-approval-roche-products-pty-ltd-covid-19-treatment-tocilizumab-actemra
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276
https://www.tga.gov.au/media-release/tga-grants-provisional-determination-roche-products-pty-ltd-covid-19-treatment-tocilizumab-actemra
https://www.expresspharma.in/msf-demands-newest-covid-19-treatment-recommended-by-who-must-be-accessible-to-all/
https://www.nzdoctor.co.nz/article/undoctored/pharmac-funds-tocilizumab-treat-cases-covid-19
https://www.smh.com.au/business/companies/extremely-limited-tga-acts-fast-to-stop-arthritis-drug-running-out-amid-covid-driven-shortage-20210908-p58py4.html
Market Place
Share 
